Bioventus entered into a multi-year agreement with Institut Biochimique, gaining exclusive U.S. distribution rights for GELSYN-3™ 3-injection hyaluronic acid product for pain relief associated with knee osteoarthritis. Bioventus plans to launch GELSYN-3 in 3Q16.
The agreement supports Bioventus’ intent to position itself as an orthobiologics leader. Other entities that compete in the 3-injection space, as summarized in the relevant product landscape in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT, include Anika, Ferring, Sanofi, Tribute Pharmaceuticals, etc.
Bioventus entered into a multi-year agreement with Institut Biochimique, gaining exclusive U.S. distribution rights for GELSYN-3™ 3-injection hyaluronic acid product for pain relief associated with knee osteoarthritis. Bioventus plans to launch GELSYN-3 in 3Q16.
Bioventus entered into a multi-year agreement with Institut Biochimique, gaining exclusive U.S. distribution rights for GELSYN-3™ 3-injection hyaluronic acid product for pain relief associated with knee osteoarthritis. Bioventus plans to launch GELSYN-3 in 3Q16.
The agreement supports Bioventus’ intent to position itself as an orthobiologics leader. Other entities that compete in the 3-injection space, as summarized in the relevant product landscape in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT, include Anika, Ferring, Sanofi, Tribute Pharmaceuticals, etc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
